Morikazu Kito | Researchain

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Morikazu Kito is active.

Explore More

Publication

Featured researches published by Morikazu Kito.

Bioorganic & Medicinal Chemistry Letters | 2008

The structure–activity relationship study on 2-, 5-, and 6-position of the water soluble 1,4-dihydropyridine derivatives blocking N-type calcium channels

Takashi Yamamoto; Seiji Niwa; Seiji Ohno; Munetaka Tokumasu; Yoko Masuzawa; Chika Nakanishi; Akira Nakajo; Tomoyuki Onishi; Hajime Koganei; Shinichi Fujita; Tomoko Takeda; Morikazu Kito; Yukitsugu Ono; Yuki Saitou; Akira Takahara; Seinosuke Iwata; Masataka Shoji

In order to find an injectable and selective N-type calcium channel blocker, we have performed the structure-activity relationship (SAR) study on the 2-, 5-, and 6-position of 1,4-dihydropyridine-3-carboxylate derivative APJ2708 (2), which is a derivative of Cilnidipine and has L/N-type calcium channel dual inhibitory activities. As a consequence of the optimization, 6-dimethylacetal derivative 7 was found to have an effective inhibitory activity against N-type calcium channels with more than 170-fold lower activity for L-type channel compared to that of APJ2708.

Bioorganic & Medicinal Chemistry Letters | 2006

Structure-activity relationship study of 1,4-dihydropyridine derivatives blocking N-type calcium channels.

Takashi Yamamoto; Seiji Niwa; Seiji Ohno; Tomoyuki Onishi; Hiroyuki Matsueda; Hajime Koganei; Hisayuki Uneyama; Shinichi Fujita; Tomoko Takeda; Morikazu Kito; Yukitsugu Ono; Yuki Saitou; Akira Takahara; Seinosuke Iwata; Masataka Shoji

Bioorganic & Medicinal Chemistry | 2006

Discovery, structure–activity relationship study, and oral analgesic efficacy of cyproheptadine derivatives possessing N-type calcium channel inhibitory activity

Takashi Yamamoto; Seiji Niwa; Satoshi Iwayama; Hajime Koganei; Shinichi Fujita; Tomoko Takeda; Morikazu Kito; Yukitsugu Ono; Yuki Saitou; Akira Takahara; Seinosuke Iwata; Hiroshi Yamamoto; Masataka Shoji

Blood | 2003

Shielding the front-strand beta 3 of the von Willebrand factor A1 domain inhibits its binding to platelet glycoprotein Ibalpha.

Arnaud Bonnefoy; Hiroshi Yamamoto; Chantal Thys; Morikazu Kito; Jos Vermylen; Marc Hoylaerts

Archive | 2001

Antithrombotic agent and anti-von willebrand factor monoclonal antibody

Mitsuyo Nagano; Hiroshi Yamamoto; Morikazu Kito; Ryota Yoshimoto; Tsuyoshi Kobayashi

Archive | 1994

Peptide having antithrombotic activity and process for producing the same

Naoyuki Fukuchi; Hiroshi Yamamoto; Mitsuyo Nagano; Morikazu Kito; Akiko Tanaka; Koichi Ishii; Tsuyoshi Kobayashi; Ryota Yoshimoto

Archive | 1995

Antithrombotic agent and anti-von willebrand factor monoclonal antibodies

Mitsuyo Nagano; Hiroshi Yamamoto; Morikazu Kito; Ryota Yoshimoto; Tsuyoshi Kobayashi

Archive | 1999

Substance with antithrombotic activity and method for detecting glycokallidin

Naoyuki Fukuchi; Fumie Futaki; Morikazu Kito; Seiichi Sato; Takayuki Kajiura; Yukitsugu Ono; Koichi Ishii; Akiko Tanaka; Junko Shinozaki; Yasuko Jojima

Archive | 2000